UC Davis corgi recovers after emergency treatment for brain inflammation
Bottom line
A 5-year-old corgi named Aika is back to normal activity after surviving a near-fatal episode of meningoencephalomyelitis at the UC Davis William R. Pritchard Veterinary Medical Teaching Hospital. According to UC Davis, neurologist Christine Toedebusch, DVM, PhD, recognized subtle but concerning neurologic changes when Aika arrived in the emergency room, including failure to right herself and reduced awareness of her surroundings. MRI raised concern for either inflammatory brain disease or histiocytic sarcoma, and late-night cerebrospinal fluid analysis by pathology resident Yael Keinan confirmed inflammatory meningoencephalomyelitis rather than cancer. Aika spent four days hospitalized and was treated aggressively, including immunosuppressive therapy with cytarabine, before returning home and ultimately resuming normal activities. (behavior.vetmed.ucdavis.edu)
Why it matters: For veterinary professionals, the case is a reminder that early neurologic disease can present with subtle signs, and that rapid escalation to advanced imaging, CSF analysis, and specialty collaboration can be decisive. UC Davis framed the case as an example of how emergency, neurology, imaging, pathology, and critical care teams can shorten time to diagnosis in dogs with suspected inflammatory CNS disease. More broadly, MUO remains a clinical diagnosis used when noninfectious inflammatory brain disease is suspected and infectious causes have not been identified, with MRI and CSF findings central to workup. Glucocorticoids remain standard first-line therapy, while cytarabine is widely used in combination protocols, though published evidence on its added benefit is mixed. A 2024 randomized controlled trial found no short-term outcome difference between corticosteroid monotherapy and corticosteroids plus cytarabine continuous-rate infusion, while a 2026 retrospective study reported that higher-dose cytarabine was well tolerated and controlled disease in many dogs, especially outside spinal cord-only MUO and presumptive necrotizing meningoencephalitis cases. (behavior.vetmed.ucdavis.edu)
What to watch: Cases like this will keep attention on how referral centers diagnose MUO earlier, and on whether newer evidence helps clarify which dogs benefit most from cytarabine-based protocols. (onlinelibrary.wiley.com)
Key facts
- Patient
- Aika, a 5-year-old corgi
- Hospital
- UC Davis William R. Pritchard Veterinary Medical Teaching Hospital
- Condition
- Meningoencephalomyelitis
- Initial signs
- Failed to right herself and had reduced awareness of surroundings
- Imaging concern
- Inflammatory brain disease or histiocytic sarcoma
- Diagnostic confirmation
- CSF analysis supported inflammatory meningoencephalomyelitis, not cancer
- Treatment
- Aggressive immunosuppressive therapy with cytarabine
- Hospital stay
- Four days
- Outcome
- Returned home and resumed normal activities
Aika, a 5-year-old corgi treated at UC Davis, recovered from a life-threatening inflammatory brain disease after clinicians rapidly recognized subtle neurologic abnormalities and moved quickly to confirm the diagnosis. The case, highlighted by the UC Davis School of Veterinary Medicine in July 2026 and adapted in dvm360, centered on meningoencephalomyelitis, a severe inflammatory condition affecting the brain and spinal cord that can deteriorate quickly without intervention. (behavior.vetmed.ucdavis.edu)
According to UC Davis, the turning point came before definitive testing: Christine Toedebusch, DVM, PhD, was in the emergency room and noticed that Aika remained on her side rather than trying to rise, behavior she considered abnormal for a young dog. Further examination with neurology resident Kimberly Worland suggested reduced environmental awareness, prompting urgent neurologic workup. MRI findings suggested either inflammatory brain disease or histiocytic sarcoma, underscoring how difficult these cases can be to distinguish at presentation. A late-evening CSF review by pathology resident Yael Keinan then helped rule out cancer and support a diagnosis of inflammatory meningoencephalomyelitis. (behavior.vetmed.ucdavis.edu)
That sequence reflects the broader challenge of MUO-spectrum disease in practice. In dogs, many inflammatory meningoencephalitis cases do not yield a confirmed infectious cause, so clinicians often rely on the umbrella term meningoencephalomyelitis of unknown origin when imaging and CSF support noninfectious CNS inflammation and infectious testing is unrevealing. Peer-reviewed and expert guidance describe MRI and CSF analysis as the core of diagnosis, while recognizing that presentation can be acute or chronic, focal or multifocal, and that small-breed dogs are overrepresented, suggesting at least some genetic predisposition. (cliniciansbrief.com)
Treatment in Aika’s case included aggressive immunosuppression with cytarabine, and she remained hospitalized for four days before discharge. That fits a common specialty approach, where glucocorticoids form the backbone of therapy and additional immunosuppressive drugs are layered in depending on severity, clinician preference, and pet parent resources. Still, the evidence base around cytarabine is evolving. A blinded randomized controlled trial published in 2024 found no difference in short-term outcomes between corticosteroid monotherapy and combined corticosteroid plus cytarabine continuous-rate infusion in dogs with MUO. (behavior.vetmed.ucdavis.edu)
At the same time, newer retrospective data suggest the story may be more nuanced. A 2026 Journal of Veterinary Internal Medicine study evaluating 43 dogs treated with 600 mg/m2 cytarabine reported that the regimen was well tolerated, with sustained remission in many cases, but outcomes were poorer in dogs with spinal cord-only MUO and in presumptive necrotizing meningoencephalitis. That doesn’t settle the question, but it does reinforce that response may vary by phenotype, disease location, and case severity. This is an inference based on the contrast between the randomized trial and the retrospective cohort, rather than a head-to-head conclusion from either study. (pubmed.ncbi.nlm.nih.gov)
Expert-oriented background sources also emphasize why these cases remain difficult to standardize. Clinician reviews note that no single protocol has been shown to be optimal for all dogs with MUO, and treatment choices often balance neurologic severity, expected steroid adverse effects, logistics, and cost. That helps explain why referral centers continue to use multimodal protocols even as the comparative evidence remains incomplete. (cliniciansbrief.com)
Why it matters: For veterinarians, Aika’s recovery is less about a feel-good outcome than about process: noticing mild but abnormal mentation, moving quickly to advanced diagnostics, and coordinating emergency, neurology, imaging, pathology, and inpatient care. In first-opinion and ER settings, the case is a practical reminder that dogs with inflammatory CNS disease may not arrive seizuring or nonambulatory; some present with only subdued behavior, altered interaction, or reluctance to rise. Early referral and fast differentiation from neoplasia or infectious disease can materially change treatment options and prognosis. (behavior.vetmed.ucdavis.edu)
What to watch: Expect continued debate over where cytarabine fits in first-line MUO treatment, especially as newer dosing studies and subtype-specific outcome data accumulate, and watch for more institutions to spotlight multidisciplinary pathways that shorten time from subtle neurologic signs to definitive treatment. (onlinelibrary.wiley.com)